Determination of biological variation of α-fetoprotein and choriogonadotropin (β chain) in disease-free patients with testicular cancer

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 12, 2010, Pages 1799-1801

  Trapé, Jaume ^a   Franquesa, Josefina ^a   Sala, Maria ^a   Domenech, Montserrat ^a   Montesinos, Jesus ^a   Catot, Sílvia ^a   Buxó, Josep ^a   Casado, Esther ^a   Fígols, Cristina ^a   Harillo, Sílvia ^a   Galobart, Judit ^a   Bella, Meritxell ^a  

^a Althaia   (Spain)

Author keywords

fetoprotein; biological variation; choriogonadotropin ( chain); reference change value

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CHORIONIC GONADOTROPIN BETA SUBUNIT;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BIOLOGICAL VARIATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; FOLLOW UP; HEALTH STATUS; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TESTIS CANCER;

ALPHA-FETOPROTEINS; CHORIONIC GONADOTROPIN; HUMANS; MALE; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; TESTICULAR NEOPLASMS;

EID: 78951474379     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.343     Document Type: Article

References (14)

1. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, et al. National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008; 54:e11-79.
2. Harris EK, Brown SS. Temporal changes in the concentration of serum constituents in healthy men. Distributions of within-person variances and their relevance to the interpretation of differences between successive measurements. Ann Clin Biochem 1979;16: 169-76.
3. Harris EK, Yasaka T. On the calculation of a "reference change" for comparing two consecutive measurements. Clin Chem 1983;29:25-30.
4. Hölzel WG, Beer R, Deschner W, Griesmacher A, Müller MM. Individual reference ranges of CA15-3, MCA and CEA in recurrence of breast cancer. Scand J Clin Lab Invest Suppl 1995;221:93-101.
5. Panteghini M, Pagani F, Bonora R. Pre-analytical and biological variability of prostatic acid phosphatase and prostate specific antigen in serum from patients with prostatic pathology. Eur J Clin Chem Clin Biochem 1992;30:135-9.
6. Mora J, Queraltó JM. Within-subject variation of carcinoembryonic antigen in colorectal cancer - application of reference change values and individual reference ranges to patient followup. Eur J Clin Chem Clin Biochem 1997;35:53-7.
7. Trapé J, Pérez de Olaguer J, Buxó J, López L. Biological variation of tumor markers and its application in the detection of disease progression in patients with non-small cell lung cancer. Clin Chem 2005;51:219-22.
8. Biosca C, Ricós C, Jimenez CV, Lauzurica R, Galimany R. Model for establishing biological variation in non-healthy situations: renal post-transplantation data. Clin Chem 1997;43: 2206-8.
9. Philipou G, Philips PJ. Intraindividual variation of glycohemoglobin: implications for interpretation and analytical goals. Clin Chem 1993;39:2305-8.
10. Trapé J, Aliart M, Brunet M, Dern E, Abadal E, Queraltó JM. Reference change value for HbA1c in patients with type 2 diabetes mellitus. Clin Chem Lab Med 2000;38:1283-7.
11. Queraltó JM, Boyd JC, Harris EK. On the calculation of reference change values, with examples from long-term study. Clin Chem 1993;39:1398-403.
12. Trapé J, Botargues JM, Porta F, Ricós C, Badal JM, Salinas R, et al. Reference change value for a-fetoprotein in early detection of hepatocellular carcinoma in patients with hepatic diseases. Clin Chem 2003;49:1209-11.
13. Ricós C, Alvarez V, Cava F, Lario JV, Hernández A, Jiménez CV, et al. Desirable specifications for total error, and bias, derived from biologic variation. in http://www.westgard.com/ biodatabase1.htm. Accessed Nov. 2009.
14. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-37.